




Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently amended) A method of treating ~~or preventing~~ a respiratory disease, comprising administering to a mammal an effective amount of a compound having matrix metalloprotease inhibitory activity and the generalized formula:



wherein

- (a) ~~(T)_xA represents a substituted or unsubstituted aromatic or heteroaromatic moiety selected from the group consisting of:~~



wherein R_1 represents H or alkyl of 1 - 3 carbons; and

each T represents a substituent group, independently selected from the group consisting of:

- * the halogens -F, -Cl, -Br, and -I;
- * alkyl of 1 - 10 carbons;
- * haloalkyl of 1 - 10 carbons;
- * haloalkoxy of 1 - 10 carbons;
- * alkenyl of 2 - 10 carbons;
- * alkynyl of 2 - 10 carbons;
- * $-(CH_2)_pQ$, wherein
p is 0 or an integer 1 - 4,
- * -alkenyl-Q, wherein
said alkenyl moiety comprises 2 - 4 carbons, and

* -alkynyl-Q, wherein
said alkynyl moiety comprises 2 - 7 carbons; and

Q is selected from the group consisting of aryl of 6 - 10 carbons, heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom, -CN, -CHO, -NO₂, -CO₂R², -OCOR², -SOR³, -SO₂R³, -CON(R⁴)₂, -SO₂N(R⁴)₂, -C(O)R², -N(R⁴)₂, -N(R²)COR², -N(R²)CO₂R³, -N(R²)CON(R⁴)₂, -CHN₄, -OR⁴, and -SR⁴;

wherein

R² represents H;
alkyl of 1 - 6 carbons;
aryl of 6 - 10 carbons;
heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;
or
arylalkyl in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons; or
heteroaryl-alkyl in which the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;

R³ represents alkyl of 1 - 4 carbons;
aryl of 6 - 10 carbons;
heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;
or

arylalkyl in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons; or
heteroaryl-alkyl in which the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;


R⁴ represents H;
alkyl of 1 - 12 carbons;
aryl of 6 - 10 carbons;
heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;
arylalkyl in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons;
heteroaryl-alkyl in which the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;
alkenyl of 2 - 12 carbons;
alkynyl of 2 - 12 carbons;
-(C_qH_{2q}O)_rR⁵ wherein q is 1-3; r is 1 - 3; and R⁵ is H provided q is greater than 1, or alkyl of 1 - 4 carbons, or phenyl;
alkylenethio terminated with H, alkyl of 1-4 Carbons, or phenyl;
alkyleneamino terminated with H, alkyl of 1-4 carbons, or phenyl;
-(CH₂)_sX wherein s is 1 - 3 and X is halogen;
-C(O)OR²; or
-C(O)R²;

and with the provisos that a) when two R⁴ groups are situated on a nitrogen, they may be joined by a bond to form a heterocycle, and b) unsaturation in a

moiety which is attached to Q or which is part of Q is separated from any N, O, or S of Q by at least one carbon atom, and


x is 0, 1, or 2;

- (b) B represents ~~a bond or~~ an optionally substituted p-phenylene ~~aromatic or hetero-~~ aromatic ring containing 0-2 substituents T, which substituents T may independently have the meaning specified under (a), ~~the B-rings being selected from the group consisting of:~~



wherein R^1 is as defined above ;

(c) D represents




in which R^2 is defined as above and each R^2 may be the same or different ;

- (d) E represents a chain of n carbon atoms bearing m substituents R^6 , wherein said R^6 groups are independent substituents, or constitute spiro or nonspiro rings in which
- two groups R^6 are joined, and taken together with the chain atom(s) to which said two R^6 group(s) are attached, and any intervening chain atoms, constitute a 3 - 7 membered ring, or
 - one group R^6 is joined to the chain on which said one group R^6 resides, and taken together with the chain atom(s) to which said R^6 group is attached, and any intervening chain atoms, constitutes a 3 - 7 membered ring; and wherein
- n is 2 or 3;
m is an integer of 1 - 3;

each group R^6 is independently selected from the group consisting of:

- * fluorine;
- * hydroxyl, with the proviso that a single carbon may bear no more than one hydroxyl substituent
- * alkyl of 1 - 10 carbons;
- * aryl of 6 - 10 carbons;
- * heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;
- * arylalkyl wherein the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 8 carbons;

- * heteroaryl-alkyl wherein the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom, and the alkyl portion contains 1 - 8 carbons;
- * alkenyl of 2 - 10 carbons;
- * aryl-alkenyl wherein the aryl portion contains 6 - 10 carbons and the alkenyl portion contains 2 - 5 carbons;
- * heteroaryl-alkenyl wherein the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkenyl portion contains 2 - 5 carbons;
- * alkynyl of 2 - 10 carbons;
- * aryl-alkynyl wherein the aryl portion contains 6 - 10 carbons and the alkynyl portion contains 2 - 5 carbons;
- * heteroaryl-alkynyl wherein the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkynyl portion contains 2 - 5 carbons;
- * $-(CH_2)_tR^7$ wherein
t is 0 or an integer of 1 - 5; and
 R^7 is selected from the group consisting of



and corresponding heteroaryl moieties in which the aryl portion of an aryl-containing R⁷ group comprises 4 - 9 carbons and at least one N, O, or S heteroatom;

wherein

Y represents O or S;


R¹, R², and R³ are as defined above; and

u is 0, 1, or 2; and

* -(CH₂)_vZR⁸ wherein

v is 0 or an integer of 1 to 4; and

Z represents



R⁸ is selected from the group consisting of:

alkyl of 1 to 12 carbons;

aryl of 6 to 10 carbons;

heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;

arylalkyl wherein the aryl portion contains 6 to 12 carbons and the alkyl portion contains 1 to 4 carbons;

heteroaryl-alkyl wherein the aryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;

-C(O)R⁹ wherein R⁹ represents alkyl of 2 - 6 carbons, aryl of 6 - 10 carbons, heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom, or arylalkyl in which the aryl portion contains 6 - 10 carbons

or is heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom, and the alkyl portion contains 1 - 4 carbons; and with the provisos that

- when R^8 is $-C(O)R^9$, Z is S or O;
- when Z is O, R^8 may also be $-(C_qH_{2q}O)_rR^5$ wherein q, r, and R^5 are as defined above; and

* $-(CH_2)_wSiR^{10}_3$ wherein
w is an integer of 1 to 3; and
 R^{10} represents alkyl of 1 to 2 carbons;

and with the proviso that

- aryl or heteroaryl portions of any of said T or R^6 groups optionally may bear up to two substituents selected from the group consisting of $-(CH_2)_yC(R^4)(R^3)OH$, $-(CH_2)_yOR^4$, $-(CH_2)_ySR^4$, $-(CH_2)_yS(O)R^4$, $-(CH_2)_yS(O)_2R^4$, $-(CH_2)_ySO_2N(R^4)_2$, $-(CH_2)_yN(R^4)_2$, $-(CH_2)_yN(R^4)COR^3$, $-OC(R^4)_2O-$ in which both oxygen atoms are connected to the aryl ring, $-(CH_2)_yCOR^4$, $-(CH_2)_yCON(R^4)_2$, $-(CH_2)_yCO_2R^4$, $-(CH_2)_yOCOR^4$, -halogen, -CHO, $-CF_3$, $-NO_2$, $-CN$, and $-R^3$, wherein


y is 0 - 4; and

R^3 and R^4 are defined as above; and any two R^4 which are attached to one nitrogen may be joined to form a heterocycle;

or a and pharmaceutically acceptable salt ~~salts and prodrugs~~ thereof.

2. (Currently amended) The method of claim 1, wherein

- (a) $(T)_x A$ represents ~~a substituted or unsubstituted aromatic or heteroaromatic moiety selected from the group consisting of:~~



wherein

each T represents a substituent group, independently selected from the group consisting of:

- * the halogens -F, -Cl, -Br, and -I;
- * alkyl of 1 - 10 carbons;
- * haloalkyl of 1 - 10 carbons;
- * alkenyl of 2 - 10 carbons;
- * alkynyl of 2 - 10 carbons;
- * $-(CH_2)_p Q$, wherein
p is 0 or an integer 1 - 4,
- * -alkenyl-Q, wherein
said alkenyl moiety comprises 2 - 4 carbons, and
- * -alkynyl-Q, wherein
said alkynyl moiety comprises 2 - 7 carbons; and

Q is selected from the group consisting of $-OR^4$ and $-SR^4$;

wherein

R^4 represents H;

alkyl of 1 - 12 carbons;

aryl of 6 - 10 carbons;

heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;

arylalkyl in which the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 4 carbons;

heteroaryl-alkyl in which the heteroaryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;

-C(O)OR²; or


-C(O)R²;

and with the proviso that unsaturation in a moiety which is attached to Q or which is part of Q is separated from any N, O, or S of Q by at least one carbon atom, and

x is 0, 1, or 2;

(b) B represents an optionally substituted phenyl ~~or thienyl~~ ring containing 0-2 substituents T, which substituents T may independently have the meaning specified under (a).

(c) D represents



(d) E represents a chain of n carbon atoms bearing m substituents R⁶, wherein said R⁶ groups are independent substituents, or constitute nonspiro rings in which two groups R⁶ are joined, and taken together with the chain atom(s) to which said two

R^6 group(s) are attached, and any intervening chain atoms, constitute a 5 or 6-membered ring; and wherein

n is 2 or 3;

m is an integer of 1 or 2;


each group R^6 is independently selected from the group consisting of:

* arylalkyl wherein the aryl portion contains 6 - 10 carbons and the alkyl portion contains 1 - 8 carbons;

* $-(CH_2)_tR^7$ wherein

t is 0 or an integer of 1 - 5; and


R^7 is selected from the group consisting of



wherein

R^2 is independently selected from the group consisting of: H; aryl of 6-10 carbons

- * $-(CH_2)_vZR^8$ wherein
 v is 0 or an integer of 1 to 4; and
 Z represents



R^8 is selected from the group consisting of:

- alkyl of 1 to 12 carbons;
- aryl of 6 to 10 carbons;
- heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom;
- arylalkyl wherein the aryl portion contains 6 to 12 carbons and the alkyl portion contains 1 to 4 carbons;
- heteroaryl-alkyl wherein the aryl portion comprises 4 - 9 carbons and at least one N, O, or S heteroatom and the alkyl portion contains 1 - 4 carbons;
- $-C(O)R^9$ wherein R^9 represents alkyl of 2 - 6 carbons, aryl of 6 - 10 carbons, heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom, or arylalkyl in which the aryl portion contains 6 - 10 carbons or is heteroaryl comprising 4 - 9 carbons and at least one N, O, or S heteroatom, and the alkyl portion contains 1 - 4 carbons;
- and with the provisos that
 - when R^8 is $-C(O)R^9$, Z is S or O;
 - when Z is O, R^8 may also be $-(C_qH_{2q}O)_rR^5$ wherein q , r , and R^5 are as defined above; and

- * $-(CH_2)_wSiR^{10}_3$ wherein

w is an integer of 1 to 3; and

R¹⁰ represents alkyl of 1 to 2 carbons;

and with the proviso that




- aryl or heteroaryl portions of any of said T or R⁶ groups optionally may bear up to two substituents selected from the group consisting of OR⁴, N(R⁴)₂, -OC(R⁴)₂O- in which both oxygen atoms are connected to the aryl ring, CON(R⁴)₂, OCOR⁴, -halogen, -NO₂, and alkyl with up to 6 carbon atoms



wherein




R⁴ is defined as above;





or a and pharmaceutically acceptable salt ~~salts and prodrugs~~ thereof.





3. (Currently amended) The method of claim 1 or 2, wherein at least one of the units ~~A~~, ~~B~~, ~~T~~, T and R⁶ comprises a heteroaromatic ring.
4. (Previously presented) The method of claim 1 or 2, wherein in said E unit, n is 2 and m is 1.
5. (Canceled)
6. (Previously presented) The method of claim 1 or 2, wherein the compound is selected from the following group:





















































- Tc1ccc(cc1)-c2ccc(cc2)C(=O)E(C(=O)O)
- (I')


wherein CO-E-CO₂H represents a 3-carboxyl-5-R⁷-pentan-1-on-1-yl- residue and the substituents T and R⁷ have the meaning indicated in the following table:

T	R ⁷	racemate, (+)- or (-)- enantiomer	
[[OEt]]		[[(+)]]	[[;]]
[[OEt]]		[[(-)]]	[[;]]
OAc		rac	;
OH		rac	;

T	R ⁷	racemate, (+)- or (-)- enantiomer	
Cl		rac	;
[[Br]]		[[(+)]]	[[;]]
[[Br]]		[[(-)]]	[[;]]
[[Cl]]		[[(+)]]	[[;]]
[[Cl]]		[[(-)]]	[[;]]
CN		rac	or
OCF ₃		rac	.

8. (Canceled)

9. (Currently amended) A method of treating ~~or preventing~~ a respiratory disease, comprising administering to a mammal an effective amount of a compound of the general formula (I')




wherein

T is (C₁-C₄)-alkoxy, chloride, bromide, fluoride, acetoxy, hydroxy, cyano, trifluoromethyl or trifluoromethoxy,


CO-E-CO₂H represents a 3-carboxyl-5-R⁷-pentan-1-on-1-yl- or a 2-carboxyl-3-(R⁷-methyl)-cyclopentan-1-yl)carbonyl-residue, and

R⁷ represents a group of the formula




and ~~their salts~~ or its salt .

10. (Currently amended) A method of treating ~~or preventing~~ a respiratory disease, comprising administering to a mammal an effective amount of the compound (+)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-4-(4'-ethoxy[1,1'-biphenyl]-4-yl)-4-oxobutanoic acid,



11. (Currently amended) A method of treating ~~or preventing~~ a respiratory disease, comprising administering to a mammal an effective amount of the compound (+)-4-(4'-

chloro[1,1'-biphenyl]-4-yl)-2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-4-oxobutanoic acid



12. (Canceled)
13. (Canceled)
14. (Original) The method of claim 1, 9, 10 or 11, wherein said respiratory disease is selected from the group consisting of asthma; chronic obstructive pulmonary diseases including chronic bronchitis and emphysema; cystic fibrosis; bronchiectasis; adult respiratory distress syndrome (ARDS); allergic respiratory disease including allergic rhinitis; diseases linked to TNF_α production including acute pulmonary fibrotic diseases, pulmonary sarcoidosis, silicosis, coal worker's pneumoconiosis, alveolar injury in mammals, such as human, a farm animal or a domestic pet.
15. (Canceled)
16. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 7 or 8 and a pharmaceutically acceptable carrier.

17. (Currently amended) A method of treating ~~or preventing~~ acute and chronic inflammatory processes, comprising administering to a mammal an effective amount of a compound according to claim 7 ~~or~~ 8.